AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04601467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of matching placebo (tablet) once daily for 12 months
Study NCT05100654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Study NCT05100654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Study NCT05100654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Study NCT05100654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Study NCT05528224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)
Description: OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate\<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention.
Study NCT05528224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Description: OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
Study NCT05528224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional medical treatment (TAU)
Description: In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
Study NCT05528224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional medical treatment (TAU)
Description: In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
Study NCT05819138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Semaglutide injection
Study NCT05819138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semaglutide placebo injection
Study NCT05942937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Intervention (The HepPEd Program)
Description: All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format.
Study NCT06393374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg intravenous (IV) infusion q6w
Study NCT06393374 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg intravenous (IV) infusion q6w
Study NCT06393374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Sacituzumab tirumotecan 4 mg/kg IV infusion q2w
Study NCT05113355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
Study NCT05113355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
Study NCT06320119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDO Group
Description: Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
Study NCT05745324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
Study NCT06177782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth modified scan bodies
Description: Tooth modified scan bodies are used during scanning for full arch implant cases.
Study NCT06177782 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional scan bodies
Description: Conventional scan bodies will be used for scanning the full arch implant cases.
Study NCT04770987 — intervention group
Intervention type: OTHER
Intervention: lateral neck flexor endurance test
Description: Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
Study NCT05329818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down.
Study NCT05329818 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high definition transcranial direct current stimulation
Description: Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down.
Study NCT04709302 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19
Description: Patients diagnosed with a COVID-19 infection
Study NCT04709302 — intervention group
Intervention type: BIOLOGICAL
Intervention: HIV
Description: Patients diagnosed HIV-positive
Study NCT04924244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We will play music of the subject's choice of genre during the procedure.
Study NCT04924244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Music
Description: No music will be played during the subject's interventional procedure
Study NCT06004245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7589831
Description: RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
Study NCT06004245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
Study NCT05752136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
Study NCT04858321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive heating
Description: 8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
Study NCT05707767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection surgery
Description: Patients undergo resection surgery in our hospital.
Study NCT06376357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Massage with roller
Description: The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
Study NCT06393374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
Study NCT04709302 — intervention group
Intervention type: DRUG
Intervention: ART
Description: Patients on ART
Study NCT05382663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alio Device
Description: Non-invasive device worn over vasculature.
Study NCT06411119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meta Oculus Quest 2™ Virtual Reality Exergaming
Description: Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
Study NCT05276050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active F8-coil delivered rTMS
Description: Multiple trains of rTMS in a day, for multiple days.
Study NCT05276050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active H-coil delivered rTMS
Description: Multiple trains of rTMS in a day, for multiple days.
Study NCT05207384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone (O2-O3) injection
Description: US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
Study NCT05207384 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Corticosteroid injection
Description: US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
Study NCT04881760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC
Study NCT04881760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05950191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)
Description: Next-generation bed net combining insecticides with different modes of action
Study NCT05950191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: long lasting insecticidal nets with PBO-pyrethroid (PermaNet)
Description: Next-generation bed net combining an insecticide with a synergist
Study NCT05950191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Behavior Change Communication
Description: The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
Study NCT05950191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Behavior Change Communication
Description: The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
Study NCT05047770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su
Description: 2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
Study NCT05047770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su
Description: 2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
Study NCT05047770 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flu D-QIV
Description: 1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
Study NCT05047770 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Flu D-QIV
Description: 1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
Study NCT05047770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: 1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
Study NCT05047770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: 1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
Study NCT01113021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon stimulation by low level laser therapy
Study NCT05201586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conditional Cash Transfer
Description: CCTs will be given to participants in the form of a pre-loaded debit card.
Study NCT05201586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interviews
Description: Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
Study NCT06450821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRIOR [Proactive Intensive Oral Review & Treatment]
Description: Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
Study NCT03834571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03834571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03834571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT03834571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03834571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Monitoring
Description: Undergo active monitoring
Study NCT03834571 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation
Study NCT03834571 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation
Study NCT05922215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Balance training
Description: The Experimental group will be given the Baseline treatment comprising of Stretching \& Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
Study NCT05922215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static balance training
Description: The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
Study NCT05922215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static balance training
Description: The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
Study NCT06125106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
Study NCT05153551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play-based assessment (RITA-T)
Description: The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program.
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFTs)
Description: Participants will have their lung function evaluated using PFTs
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test (6MWT)
Description: Participants >35 years of age will perform the six minute walk test as a measure of exercise capacity
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity